Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 9:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 323 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Ring Phototherapy Clear all
Completed Phase 1 Interventional

Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)

NCT01381354
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Progressive exercise, Neuromuscular electrical stimulation delivered using the electrical therapy device EMPI 300 PV, Modified paleolithic diet, Omega 3 fatty acids, Full Spectrum vitamin, Essential - hydroxytyrosol, Maltodextrin fiber supplement, Mineral boost (magnesium), Niacinamide, Methyl B12, Taurine, creatine, thiamine, riboflavin, N acetylcysteine, alpha lipoic acid, L acetyl carnitine, methyl folate, coenzyme Q, meditation, self massage, learning, Coconut oil
Other · Device · Dietary Supplement + 1 more
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Oct 22, 2026, 9:26 AM EDT
Active, not recruiting Phase 2 Interventional

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients

NCT05014646
View directory record Official record
Conditions
Smoldering Plasma Cell Myeloma
Interventions
Cholestyramine, Leflunomide
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Duarte, California • Detroit, Michigan • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 22, 2026, 9:26 AM EDT
Not listed Phase 2 Interventional

Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer

NCT00323583
View directory record Official record
Conditions
Adenocarincoma of Pancreas, Stage III Pancreatic Cancer, Stage IVA Pancreatic Cancer, Stage IVB Pancreatic Cancer
Interventions
paclitaxel, oxaliplatin, leucovorin, 5-fluorouracil, glutathione, calcium and magnesium, Chemotherapy, Chemoprotection, Complementary and alternative therapy
Drug · Procedure
Lead sponsor
Seattle Cancer Treatment and Wellness Center
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 8, 2007 · Synced Oct 22, 2026, 9:26 AM EDT
Completed Phase 3 Interventional Results available

Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma

NCT00884741
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma
Interventions
3-Dimensional Conformal Radiation Therapy, Bevacizumab, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Placebo, Quality-of-Life Assessment, Temozolomide
Radiation · Biological · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
324
States / cities
Mobile, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 262 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 22, 2026, 9:26 AM EDT
Completed Phase 4 Interventional

Treatment and Outcome of Early Onset Bipolar Disorder

NCT00048802
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium, Olanzapine, Divalproex, Risperidone, Quetiapine, Ziprasidone, Aripriprazole
Drug
Lead sponsor
Northwell Health
Other
Eligibility
10 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2014 · Synced Oct 22, 2026, 9:26 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Lavender vs Zolpidem Sleep Quality During Diagnostic PSG

NCT04102345
View directory record Official record
Conditions
Sleep
Interventions
Lavender Aromatherapy, Zolpidem
Other · Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Maplewood, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Oct 22, 2026, 9:26 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)

NCT02082522
View directory record Official record
Conditions
Hilar Cholangiocarcinoma
Interventions
Photodynamic therapy-Photofrin, Stenting procedure, Chemotherapy regimen
Drug · Procedure
Lead sponsor
Concordia Laboratories Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
18
States / cities
Goodyear, Arizona • Scottsdale, Arizona • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 22, 2026, 9:26 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension

NCT01484431
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Tadalafil- Tablet or Oral suspension
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Months to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
5
States / cities
Aurora, Colorado • Atlanta, Georgia • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Oct 22, 2026, 9:26 AM EDT
Terminated Not applicable Interventional Results available

Melatonin for Circadian Sleep Disorders in the Blind

NCT00911053
View directory record Official record
Conditions
Insomnia, Blindness, Daytime Sleepiness
Interventions
Melatonin, Regular Sleep Schedule, Light
Drug · Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 100 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 22, 2026, 9:26 AM EDT
Completed Phase 4 Interventional Results available

Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus

NCT02046395
View directory record Official record
Conditions
Type 2 Diabetes, Hypertension
Interventions
amlodipine, hydralazine, terazosin or hydrochlorothiazide
Drug
Lead sponsor
Tulane University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 22, 2026, 9:26 AM EDT
Not listed Phase 3 Interventional

Corneal Cross-Linking Comparing Variables

NCT02095730
View directory record Official record
Conditions
Unstable Corneas
Interventions
Epithelium-On Riboflavin, Epithelium-Off Riboflavin, UV Light - Continuous Beam, UV Pulsed Beam
Drug · Device
Lead sponsor
Crowd Health Research, LTD
Other
Eligibility
12 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
16
States / cities
Santa Rosa, California • Denver, Colorado • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2014 · Synced Oct 22, 2026, 9:26 AM EDT
Terminated Phase 2 Interventional

CXL-04 A Study of Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas

NCT01956474
View directory record Official record
Conditions
Keratoconus
Interventions
Theralight crosslinking and Riboflavin
Other
Lead sponsor
Cxlusa
Industry
Eligibility
8 Years and older
Enrollment
1,324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
6
States / cities
Miami, Florida • Atlanta, Georgia • Rockville, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 22, 2026, 9:26 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers Results available

Opioid-Free Pain Protocol After Shoulder Arthroplasty

NCT05488847
View directory record Official record
Conditions
Shoulder Arthropathy, Shoulder Pain
Interventions
Celecoxib, Pregabalin, Tramadol, Dexamethasone, Acetaminophen, Ropivicaine, Epinephrine, Ketorolac, Tizanidine, Magnesium, Ibuprofen, Oxycodone Hydrochloride 5 Mg
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 22, 2026, 9:26 AM EDT
Terminated Phase 3 Interventional Results available

Safety Study of the VEGA UV-A System to Treat Ectasia

NCT01398839
View directory record Official record
Conditions
Ectasia
Interventions
VEGA UV-A Illumination System, Riboflavin
Device · Drug
Lead sponsor
Topcon Medical Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
12
States / cities
Phoenix, Arizona • Atlanta, Georgia • Bloomington, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Oct 22, 2026, 9:26 AM EDT
Recruiting Phase 2 Interventional

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

NCT04981509
View directory record Official record
Conditions
Hereditary Leiomyomatosis and Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma, Sporadic Papillary Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Atezolizumab, Bevacizumab, Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Computed Tomography with Contrast, Erlotinib, Magnetic Resonance Imaging, Positron Emission Tomography, Sodium Fluoride F-18
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
13
States / cities
La Jolla, California • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 22, 2026, 9:26 AM EDT
Terminated Early Phase 1 Interventional

Study to Compare Different Light Therapies (Narrowband Ultraviolet B vs PUVA) for Hand and Foot Skin Diseases.

NCT00217009
View directory record Official record
Conditions
Dermatitis, Psoriasis
Interventions
Narrowband Ultraviolet B (TL-01UVB) Therapy, Topical Psoralen plus ultraviolet A (PUVA)
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Oct 22, 2026, 9:26 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder

NCT02559973
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
RBP-6000, SUBOXONE Sublingual Film
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Oct 22, 2026, 9:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Understanding Physiology During Float-REST and the Consequential Effects on Subjective and Objective Recovery

NCT04415970
View directory record Official record
Conditions
Sleep Quality
Interventions
Flotation therapy sensory deprivation tank, Sleep Pod
Other
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Oct 22, 2026, 9:26 AM EDT
Recruiting Phase 2Phase 3 Interventional

Corneal Crosslinking for Treatment of Progressive Keratoconus or Corneal Ectasia

NCT07841470
View directory record Official record
Conditions
Keratoconus, Corneal Ectasia
Interventions
Riboflavin 0.1% ophthalmic solution and pulsed light, Riboflavin 0.1% ophthalmic solution and non-pulsed light
Combination Product
Lead sponsor
Price Vision Group
Industry
Eligibility
10 Years to 90 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 22, 2026, 9:26 AM EDT
Completed Phase 3 Interventional Results available

The Clinical Utility of Measuring the Circadian Clock in Treatment of Delayed Sleep-Wake Phase Disorder

NCT03715465
View directory record Official record
Conditions
Delayed Sleep Phase Syndrome
Interventions
Melatonin 0.5 MG, Dim Light Melatonin Onset (salivary)
Drug · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 25, 2022 · Synced Oct 22, 2026, 9:26 AM EDT
Recruiting Phase 1 Interventional

Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies

NCT05443425
View directory record Official record
Conditions
Acute Graft Versus Host Disease, Hematopoietic and Lymphoid System Neoplasm
Interventions
Cholestyramine, Leflunomide, Steroid Therapy
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 22, 2026, 9:26 AM EDT
Completed Phase 2 Interventional Results available

Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis

NCT00458822
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
bortezomib, dexamethasone
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Oct 22, 2026, 9:26 AM EDT
Completed Phase 4 Interventional Results available

Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea

NCT03380390
View directory record Official record
Conditions
Rosacea
Interventions
Oxymetazoline HCL 1.0% Cream, Energy-Based Therapy
Drug · Device
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Sacramento, California • Chestnut Hill, Massachusetts • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 22, 2026, 9:26 AM EDT
Recruiting Phase 4 Interventional

Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension

NCT05593055
View directory record Official record
Conditions
Hypertension, Left Ventricular Hypertrophy
Interventions
Eplerenone, Chlorthalidone, Potassium
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 22, 2026, 9:26 AM EDT